Novo, Sandoz Reach Deal Over Generic Prandin
Novo Nordisk Inc. has agreed to drop infringement allegations against Sandoz Inc. over two claims of a patent for diabetes drug Prandin, in exchange for Sandoz's admission that it infringed three...To view the full article, register now.
Already a subscriber? Click here to view full article